Skip to main content
Monday, November 16, 2026Nov 16

Novavax says protein vaccine works for kids as young as 12

FILE - A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in London on Wednesday, Oct. 7, 2020. On Thursday, Feb. 10, 2022, Novavax announced that its protein-based COVID-19 vaccine proved safe and effective in a study of 12- to 17-year-olds. (AP Photo/Alastair Grant, File)
FILE - A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in London on Wednesday, Oct. 7, 2020. On Thursday, Feb. 10, 2022, Novavax announced that its protein-based COVID-19 vaccine proved safe and effective in a study of 12- to 17-year-olds. (AP Photo/Alastair Grant, File)

Novavax has announced that its COVID-19 vaccine proved safe and effective in a study of 12- to 17-year-olds.

Novavax makes a protein-based vaccine — a different type than the most widely used shots — that’s a late arrival to the COVID-19 arsenal.

Its shots have been cleared for use in adults by regulators in Britain, Europe and elsewhere and by the World Health Organization, and are under review by the U.S. Food and Drug Administration.

Armed with the new data, Novavax plans to soon seek expanded use of its shots down to age 12. Later this year, it plans to begin testing in younger children.

The latest study enrolled 2,247 U.S. kids ages 12 to 17 last summer and found the two-dose vaccine was 80% effective at preventing symptomatic COVID-19 infection.